367
Views
1
CrossRef citations to date
0
Altmetric
Special Section: Estimands, Design and Analysis of Clinical Trials with Time-to-Event Outcomes

Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”

ORCID Icon, &
Pages 310-311 | Received 20 May 2022, Accepted 24 May 2022, Published online: 10 Aug 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yuan-Li Shen, Sirisha Mushti, Flora Mulkey, Thomas Gwise, Xin Wang, Jiaxi Zhou, Xin Gao, Shenghui Tang, Marc R. Theoret, Richard Pazdur & Rajeshwari Sridhara. (2023) Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”. Statistics in Biopharmaceutical Research 15:2, pages 315-317.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.